Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF

  • 0 views
  • 29 Oct, 2022
  • 4 locations
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

This phase II trial studies the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical (Haplo) transplantation for the treatment of primary or secondary myelofibrosis (MF

  • 8 views
  • 06 Jun, 2022
  • 1 location
Low-frequency Pulsed Electromagnetic Fields (ELF-MF) as Treatment for Acute Ischemic Stroke (I-NIC)

The main purpose of this multicentric, prospective, randomized, placebo-controlled, double-blind study is the validation of pulsed ELF-MF stimulation as non-invasive and safe tool to promote

ischemic stroke
infarct
stroke
  • 0 views
  • 23 Feb, 2022
  • 1 location
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma (IMAGINE)

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid …

cyclophosphamide
large cell lymphoma
fludarabine
flow cytometry
experimental drug
  • 2 views
  • 22 Oct, 2022
  • 5 locations
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the

  • 0 views
  • 04 Oct, 2022
  • 2 locations
Multifocal Electroretinogram in Normal Egyptian Population

Studying normal subjects to create unique normal database for multifocal electroretinogram (mf-ERG) in specific population.

Accepts healthy volunteers
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene

mycosis fungoides
cancer
topical steroids
lymphoma
cutaneous t-cell lymphoma
  • 0 views
  • 16 Oct, 2022
  • 1 location
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red …

white blood cells
serum pregnancy test
monoclonal antibodies
immunoglobulin
lymphoma
  • 0 views
  • 07 Oct, 2022
  • 1 location
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

  • 0 views
  • 04 Oct, 2022
  • 1 location
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell

cancer
chronic myelomonocytic leukemia
  • 0 views
  • 04 Oct, 2022
  • 1 location